Influencers are pushing false claims about SPF. Doctor explains why they are wrong
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Apple's blood oxygen monitoring returns to its latest Apple Watches
Apple announced on Thursday it's introducing a redesigned Blood Oxygen feature for some Watch Series 8, Series 10, and Apple Watch Ultra. With this move, Apple is bringing back blood oxygen monitoring by tweaking the feature to get around the International Trade Commission's (ITC) import ban. Blood oxygen data will be measured and calculated on the user's paired iPhone, and results can be viewed in the Respiratory section of the Health app. This means users won't be able to view the data on their Apple Watch, as they'll need to do so on their iPhone. Apple says the update announced today is enabled by a recent U.S. Customs ruling, which means that the tech giant is allowed to import Apple Watches with the redesigned Blood Oxygen feature. The change doesn't affect previously sold models with the original version of the feature or units bought outside the U.S. The redesigned feature only applies to Apple Watches that were sold after the ITC import ban took effect in early 2024. These users can access the redesigned Blood Oxygen feature through an iPhone and Apple Watch software update coming on Thursday. The move comes as Apple has been in an ongoing legal dispute with medical device maker Masimo, which has accused the tech giant of stealing its pulse oximetry technology after initial talks about a potential collaboration. In 2023, Masimo secured a victory against Apple at the ITC to block imports of Apple Watches with blood oxygen monitoring, after the commission found that Apple's technology infringed upon Masimo's patents. Apple then had to remove the feature. Apple counter-sued Masimo, claiming that the company copied Apple Watch features to use in its own smartwatches. The tech giant has also filed an appeal of the ITC ban. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Digital Trends
21 minutes ago
- Digital Trends
Blood oxygen measurement returns to the Apple Watch, sort of
Apple has just announced a software update that will enable the missing blood oxygen level measurement capability on the Apple Watch. The update will enable the biosensing feature on the Watch Series 9, Series 10, and the Apple Watch Ultra 2, once users update their iPhone and smartwatch to the latest build. What does it mean for users? In order to use the blood oxygen feature again on the Apple Watch Series 9, 10, and the Ultra 2, users will have to update their smartwatch to watchOS 11.6.1. The update is now rolling out to users in the United States. In addition to it, the feature will only work when users also update their iPhone to iOS 18.6.1, which has also been released simultaneously. Recommended Videos There's a crucial difference this time around. Instead of seeing the blood oxygen measurement on the Apple Watch screen, users will now have to open the Health app on their iPhone. That's because Apple is now doing the computation on the iPhone, instead of accomplishing it on the wearable and showing the results natively on the Apple Watch due to the patent dispute over alleged theft of the underlying pulse oximetry tech. 'Sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app,' instructs Apple. For all other Apple Watch models not affected by the patent dispute, they will continue to measure and show the measurements in the Blood Oxygen app on the smartwatch's screen. Why the hassle? So far, Apple Watch users have been able to track their blood oxygen saturation levels on their Apple Watch and see the readings on their wrists. But owing to a patent dispute with a company named Masimo and an import ban on models that offer this feature, the Cupertino-based company had to pull this capability after lengthy legal battles and an import ban handed down by the International Trade Commission The ban came into effect back in December of 2023, and despite a brief respite, Apple had to disable the blood oxygen features on the watches it sold following the trade restriction in the US. Apple has expressed disagreement with the charges leveled against it by Masimo, after the company filed two seprate lawsuits against the Apple Watch maker. Interestingly, Apple began working on a software-based workaround soon after the ITC ruling. It appears that the company was ready with an alternative route, but it's surprising that Apple took over a year and a half to enable it.
